Literature DB >> 11953041

Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide.

H Einsele1, G Rauser, U Grigoleit, H Hebart, C Sinzger, S Riegler, G Jahn.   

Abstract

BACKGROUND: CMV disease is still associated with a high morbidity and mortality in recipients of a solid organ or stem cell graft, especially in patients undergoing allogenic stem cell transplantation. Reconstitution of CMV-specific CD4(+) and CD8(+) cytotoxic T cell responses are essential to control CMV infection following allogenic stem cell transplantation. The transfer of unselected populations of lymphocytes from the peripheral blood of a CMV-scropositive donor to a transplant recipient can be used to control CMV infection. However, such transfer of unselected donor lymphocytes is limited by potentially fatal complications that arise from alloreactive T cells, also present in the unselected donor lymphocytes. Thus to make infusion of donor T cells safe and also more effective in controlling CMV infection in the recipient of the T cell infusion, T cells are manipulated in vitro to deplete alloreactive T cells and to enrich for CMV-specific T cells.
METHODS: Using various antigen-presenting cells (monocytes/PBMNCs/dendritic cells) and different modes of antigen presentation (infected APCs, pulsing of protein or peptide antigen) different CMV-specific T cell populations can be generated and expanded.
RESULTS: Using protein-/or peptide-pulsed DCs CMV-specific CD8(+) cytoxic T cell lines (can be generated and expanded) in addition CMV-specific CD4(+) T cell lines can be generated when CMV-protein-pulsed DCs are used as antigen-presenting cells. When peripheral blood mononuclear cells were stimulated with CMV lysates predominantly CMV-specific CD4(+) T cells are generated and expanded ex vivo. DISCUSSION: Depending on the APC used (monocytes versus DC) and the mode of antigen presentation (protein versus peptide pulsing) different CMV-specific T cell populations of varying purity can be generated which show preserved function when tested for specific proliferation, cytokine production and cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11953041     DOI: 10.1080/146532402317251527

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  6 in total

1.  In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes.

Authors:  Kyung-Duk Park; Luciana Marti; Joanne Kurtzberg; Paul Szabolcs
Journal:  Blood       Date:  2006-05-04       Impact factor: 22.113

2.  Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

Authors:  Corinna La Rosa; Jeffrey Longmate; Chetan Raj Lingaraju; Qiao Zhou; Teodora Kaltcheva; Nicola Hardwick; Ibrahim Aldoss; Ryotaro Nakamura; Don J Diamond
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-16       Impact factor: 5.742

3.  Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Authors:  Conrad R Cruz; Ulrike Gerdemann; Ann M Leen; Jessica A Shafer; Stephanie Ku; Benjamin Tzou; Terzah M Horton; Andrea Sheehan; Amanda Copeland; Anas Younes; Cliona M Rooney; Helen E Heslop; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

Review 4.  Cytotoxic T lymphocytes as immune-therapy in haematological practice.

Authors:  Ann M Leen; Helen E Heslop
Journal:  Br J Haematol       Date:  2008-08-07       Impact factor: 6.998

5.  Immune responses of human immature dendritic cells can be modulated by the recombinant Aspergillus fumigatus antigen Aspf1.

Authors:  Michael Ok; Jean Paul Latgé; Carina Baeuerlein; Frank Ebel; Markus Mezger; Max Topp; Oliver Kurzai; Doreen Killian; Markus Kapp; Goetz-Ulrich Grigoleit; Helga Sennefelder; Javier Arroyo; Hermann Einsele; Juergen Loeffler
Journal:  Clin Vaccine Immunol       Date:  2009-08-12

6.  Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.

Authors:  Ulrike Gerdemann; Anne S Christin; Juan F Vera; Carlos A Ramos; Yuriko Fujita; Hao Liu; Dagmar Dilloo; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Ann M Leen
Journal:  Mol Ther       Date:  2009-07-07       Impact factor: 11.454

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.